

Stanford Cancer Institute

Cutaneous Oncology

Version Date: **November 10, 2023**

Mucosal Melanoma Resected R0 or R1 OR Non-Resected R2 **ECOG-ACRIN-**A091903 Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma PI: Reddy Sponsor: **ECOG-ACRIN**

